A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to mCRC
Related studies linked through entity extraction aliases.
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
MA-CRC-II-016 SHR-1811
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- Status
- RECRUITING
- Phase
- PHASE2
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
LifePearl-Iri Pharmacokinetic Study
- Status
- COMPLETED
- Phase
- NA